AHAbdullah Hussain

Abdullah Hussain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdullah Hussain has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Topical Insulin in Atrophic Acne Scarring: A Systematic Review of Efficacy, Safety, and Patient Satisfaction

    by Ahmed A. Yusuf Alaysereen, Abdullah Hussain, Bushra Hasan, Ali Zayer, Abdu-Alaziz Khaskieh, Salim Fredericks, Bindhu Nair, Aysha Al-Moosa

    Background: Atrophic acne scars are challenging to treat and have a negative psychological impact. Insulin has been tried as a topical adjuvant and stimulates fibroblast activity, collagen deposition, and keratinocyte migration. Objectives: To evaluate topical insulin for atrophic acne scars in terms of its effectiveness, safety, and patient-rated results. Methods: Five databases were searched for research on topical insulin, either alone or in conjunction with a procedure, without regard to the date. Records were screened, extracted, and evaluated in duplicate (RoB 2 or ROBINS-I) each by two independent researchers, using Covidence. Results: Fourteen studies with 619 patients, seven randomized and seven non-randomized, were qualified. All insulin arms improved from baseline (35.8% to 55.4%), but comparator arms mostly improved similarly; five studies, none at low risk of bias, favored insulin. Adverse effects were mostly local, minor, and transient, although one study reported systemic hypoglycemia-related symptoms; glucose monitoring was inconsistent, and satisfaction was high. Limitations: Meta-analysis was not possible due to heterogeneity in design, dosage, and outcome scales, and the small number of patients precludes certain conclusions. Conclusions: Although its superiority over current adjuncts has not been demonstrated, topical insulin appears to be an affordable, well-tolerated adjunct that may have a function where traditional therapies are unavailable; larger studies are needed.

  • Open Access

    Evolution of Biosensors and Current State-of-the-Art Applications in Diabetes Control

    by Yahya Waly, Abdullah Hussain, Abdulrahman Al-Majmuei, Mohammad Alatoom, Ahmed J. Alaraibi, Ahmed Alaysereen, G. Roshan Deen

    Diabetes is a chronic metabolic disorder that poses a growing global health challenge, currently affecting nearly 500 million people. Over the past four decades, the rising prevalence of diabetes has highlighted the urgent need for innovations in monitoring and management. Traditional enzymatic methods, including those using glucose oxidase, glucose dehydrogenase, and hexokinase, are widely adopted due to their specificity and relative ease of use. However, they are hindered by issues of instability, environmental sensitivity, and interference from other biomolecules. Non-enzymatic sensors, which employ metals and nanomaterials for the direct oxidation of glucose, offer an attractive alternative. These platforms demonstrate higher sensitivity and cost-effectiveness, though they remain under refinement for routine use. Non-invasive glucose detection represents a futuristic leap in diabetes care. By leveraging alternative biofluids such as saliva, tears, sweat, and breath, these methods promise enhanced patient comfort and compliance. Nonetheless, their limited sensitivity continues to challenge widespread adoption. Looking forward, the integration of nanotechnology, wearable biosensors, and artificial intelligence paves the way for personalized, affordable, and patient-centered diabetes management, marking a transformative era in healthcare. This review explores the evolution of glucose monitoring, from early chemical assays to advanced state-of-the-art nanotechnology-based approaches.


  • Open Access

    Prognostic Value of Heart‐Type Fatty Acid‐Binding Protein in Patients With Acute Coronary Syndrome: A Systematic Review and Meta‐Analysis

    by Ahmed Elmewafy, Eyad Jamileh, Abdullah Hussain, Loay Kamel, Omar Farooq, Hany Gamal, Ibrahim Antoun

    Introduction: Heart‐type fatty acid‐binding protein (H‐FABP) is rapidly released following myocardial injury, but its prognostic significance in acute coronary syndrome (ACS) remains uncertain. We evaluated the association between elevated H‐FABP and adverse clinical outcomes in confirmed or suspected ACS. Methods: PubMed, Embase, CENTRAL, Web of Science and Scopus were searched from inception to 30 August 2026 without date restriction. Studies assessing diagnostic and/or prognostic relevance of circulating H‐FABP in adults with confirmed or suspected ACS were eligible. Prognostic outcomes included all‐cause mortality, major adverse cardiovascular events (MACE), heart failure (HF)–related hospitalisation and recurrent myocardial infarction (MI). Risk of bias was assessed using QUIPS. Crude odds ratios (ORs) from extractable 2 × 2 event data were pooled using inverse‐variance random‐effects models with restricted maximum‐likelihood estimation. Results: Twelve studies were included, with five contributing to meta‐analysis. Elevated H‐FABP was associated with higher odds of all‐cause mortality (OR 5.68; 95% CI 3.98–8.09; I 2 = 30 % ), MACE (OR 4.56; 95% CI 1.97–10.55; I 2 = 47 % ), HF‐related hospitalisation (OR 4.29; 95% CI 2.94–6.26; I 2 = 0 % ) and recurrent MI (OR 1.65; 95% CI 1.15–2.37; I 2 = 0 % ). Pooled estimates were unadjusted; seven studies were synthesised narratively. Conclusion: Elevated H‐FABP is associated with adverse outcomes in ACS, but current evidence does not establish independent prognostic value. Further prospective studies should determine whether H‐FABP adds predictive value beyond established clinical and biochemical risk markers.

  • Open Access

    Reclassification of Hypophosphatemic Bone Disease as X-Linked Hypophosphatemia Following Genetic Testing in Adulthood

    by Loay Kamel, Abdullah Hussain, Ahmed Elmewafy, Dalal S. Ali, Aliya A. Khan